Publication Name	World Journal of Clinical Cases
Manuscript ID	58038
Country	China

Received	2020-09-08 16:50
Peer-Review Started	2020-09-08 16:50
To Make the First Decision
Return for Revision	2020-11-20 06:53
Revised	2020-12-03 11:55
Second Decision	2020-12-22 12:46
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief	2020-12-23 05:10
Articles in Press	2020-12-23 05:10
Publication Fee Transferred
Edit the Manuscript by Language Editor	2021-01-06 23:57
Typeset the Manuscript	2021-02-04 03:29
Publish the Manuscript Online	2021-02-06 11:08

ISSN	2307-8960 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Copyright	© The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Oncology
Manuscript Type	Case Report
Article Title	Efficacy of afatinib in patients with rare EGFR (G724S/R776H) mutations and amplification in lung adenocarcinoma: A case report
Manuscript Source	Unsolicited Manuscript
All Author List	Shu-Yan He, Qing-Feng Lin, Jie Chen, Gui-Ping Yu, Jun-Ling Zhang and Dong Shen
ORCID	Author(s) ORCID Number Shu-Yan He http://orcid.org/0000-0002-2975-5883 Qing-Feng Lin http://orcid.org/0000-0003-1994-8945 Jie Chen http://orcid.org/0000-0002-7536-8171 Gui-Ping Yu http://orcid.org/0000-0002-9665-1225 Jun-Ling Zhang http://orcid.org/0000-0002-8618-3471 Dong Shen http://orcid.org/0000-0002-9665-1224
Funding Agency and Grant Number
Corresponding Author	Dong Shen, PhD, Chief Doctor, Department of Medical Oncology, The Jiangyin Clinical College of Xuzhou Medical University, No. 163 Shoushan Road, Jiangyin 214400, Jiangsu , China. sdshendong@126.com
Key Words	EGFR G724S and R776H; Afatinib; Non-small-cell lung cancer; Case report
Core Tip	EGFR represents the first identified targetable oncogenic driver discovered in NSCLC. The most common EGFR mutations are in-frame deletions in exon 19 and exon 21. However, rare mutations were found in nearly 10-15% of EGFR-positive NSCLC and NSCLC with rare co-mutations had significantly different responses to EGFR TKI. Herein, we described a rare case of rare EGFR G724S/R776H mutations and amplification in a NSCLC responding to afatinib.
Publish Date	2021-02-06 11:08
Citation	He SY, Lin QF, Chen J, Yu GP, Zhang JL, Shen D. Efficacy of afatinib in patients with rare EGFR (G724S/R776H) mutations and amplification in lung adenocarcinoma: A case report. World J Clin Cases 2021; 9(6): 1329-1335
URL	https://www.wjgnet.com/2307-8960/full/v9/i6/1329.htm
DOI	https://dx.doi.org/10.12998/wjcc.v9.i6.1329

Full Article (PDF)	WJCC-9-1329.pdf
Full Article (Word)	WJCC-9-1329.docx
CARE Checklist–2016	58038-CARE-Checklist–2016-revision.pdf
Manuscript File	58038_Auto_Edited_WangTQ.docx
Answering Reviewers	58038-Answering reviewers.pdf
Audio Core Tip	58038-Audio core tip.m4a
Conflict-of-Interest Disclosure Form	58038-Conflict-of-interest statement.pdf
Copyright License Agreement	58038-Copyright license agreement.pdf
Signed Informed Consent Form(s) or Document(s)	58038-Informed consent statement.pdf
Non-Native Speakers of English Editing Certificate	58038-Language certificate.pdf
Peer-review Report	58038-Peer-review(s).pdf
Scientific Misconduct Check	58038-Scientific misconduct check.pdf
Scientific Editor Work List	58038-Scientific editor work list.pdf